Rallybio (NASDAQ:RLYB) Shares Up 1% – What’s Next?

Rallybio Corporation (NASDAQ:RLYB) shares traded up 1% during trading on Monday . The stock traded as high as $16.15 and last traded at $15.89. 124,711 shares were traded during mid-day trading, an increase of 214% from the average session volume of 39,658 shares. The stock had previously closed at $15.73.

Analyst Ratings Changes

Several research analysts have recently weighed in on RLYB shares. Wall Street Zen upgraded shares of Rallybio to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rallybio in a research report on Friday, May 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Rallybio currently has an average rating of “Sell”.

Rallybio Price Performance

The firm’s 50-day moving average price is $15.42 and its 200-day moving average price is $10.02. The company has a market cap of $84.22 million, a price-to-earnings ratio of -3.66 and a beta of -0.90.

Rallybio (NASDAQ:RLYB) last issued its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.21 million.

Insiders Place Their Bets

In related news, major shareholder Adar1 Capital Management, Llc purchased 120,804 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was purchased at an average price of $13.97 per share, for a total transaction of $1,687,631.88. Following the acquisition, the insider directly owned 744,683 shares in the company, valued at $10,403,221.51. The trade was a 19.36% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders purchased 302,473 shares of company stock valued at $4,229,715. 10.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RLYB. Citadel Advisors LLC lifted its position in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares in the last quarter. Susquehanna International Group LLP increased its stake in Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares during the period. XTX Topco Ltd increased its stake in Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after buying an additional 38,205 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares in the last quarter. 90.34% of the stock is owned by institutional investors and hedge funds.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.